New thrombin and factor Xa inhibitors for primary and secondary prevention of ischaemic stroke
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractAtrial fibrillation is a major risk factor for first and recurrent ischaemic stroke, and anticoagulation, mainly by use of coumarin medications, is an effective strategy for reducing ischaemic stroke occurrence in these patients. However, the coumarin medications have disadvantages. Over the past decade, important strides have been made towards developing improved anticoagulant medications. This review discusses these new developments and what they mean for the future of primary and secondary ischaemic stroke prevention in patients with atrial fibrillation. Relevant papers were identified with electronic searches of the Medline and EMBASE databases. Ongoing trials were checked using the Trials Results Centre website. The direct thrombin inhibitors, and the factor Xa inhibitors are the two major new anticoagulant drug classes under development at present. In phase III trials, dabigatran and rivaroxaban demonstrated at least as good performance as warfarin at reducing the rate of ischaemic stroke, systemic embolus, and haemorrhagic ischaemic stroke, whilst maintaining a comparable or lower rate of major bleeding events. Drug level monitoring was not required due to stable pharmacodynamics. AZD0837, apixaban, YM-150, edoxaban and betrixaban all showed promising results in phase II trials, as did S35972 in animal, in vitro and ex vivo models. The future of these new anticoagulants looks encouraging, although there are still some significant challenges to overcome. We need to consider the accumulation of long-term safety and efficacy data, and the development of effective means of reversal of anticoagulation for the direct thrombin inhibitors and factor Xa inhibitors.
CitationWinstanley, L., and Chen, R. (2013). New thrombin and factor Xa inhibitors for primary and secondary prevention of ischaemic stroke. CNS & Neurological Disorders-Drug Targets, 12(2), pp. 242-251.
JournalCNS & Neurological Disorders - Drug Targets
The following license files are associated with this item:
- Oral IIa and Xa inhibitors for prevention of stroke in atrial fibrillation: clinical studies and regulatory considerations.
- Authors: Deftereos S, Tsounis D, Giannopoulos G, Kossyvakis C, Panagopoulou V, Raisakis K, Stefanadis C
- Issue date: 2012 Aug
- Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
- Authors: Stewart RA
- Issue date: 2011 Jul
- The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
- Authors: Diener HC, Eikelboom J, Granger CB, Hacke W
- Issue date: 2012 Feb
- Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
- Authors: Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY
- Issue date: 2012 Jun
- Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.
- Authors: Schirmer SH, Baumhäkel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, Böhm M
- Issue date: 2010 Dec 14